Dr. Burgess on Treatment Considerations for PARP Inhibitors in Prostate Cancer
Earle Burgess, MD, discusses treatment considerations for PARP inhibitor use in patients with prostate cancer.
Related Articles
Revisit Every OncLive On Air Episode from March 2024
In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.
Quality Over Quantity: What Concierge Medicine Can Offer to Patients With Cancer and Employers
The current health care economy has driven many employers to self-funding models to offer affordable health care coverage to employees.
March Approval Madness: OncLive’s Roundup of FDA Decisions in Oncology
In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.
Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer
Dana M. Chase, MD, FACOG, discusses the antibody-drug conjugate tisotumab vedotin including its mechanism of action, its accelerated approval for patients with recurrent cervical cancer…
Nivolumab plus Ipilimumab vs Chemotherapy as First-line Treatment for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: First Results of the CheckMate 8HW Study
In his discussion of the CHECKMATE 8HW trial, Dr. Tanios Bekaii-Saab examined the efficacy of chemotherapy versus nivolumab plus ipilimumab as the initial treatment for…
Decreasing Grade 3/4 Infections, Limited Hospitalizations Underscore Potential for Linvoseltamab in R/R Myeloma
Sundar Jagannath, MBBS, discusses linvoseltamab and expands on key efficacy and safety findings from the LINKER-MM1 trial in patients with relapsed/refractory multiple myeloma.
More Than 25% of Cancer Survivors Report Significant Levels of Disability After Cancer Diagnosis, According to New Study
A survey of cancer survivors found that over a quarter had a physical disability impairing mobility and almost 10% had a disability affecting self-care.
ODAC Decisions Confirm Benefit of Ide-Cel and Cilta-Cel in Earlier Line R/R Myeloma Therapy
Kenneth C. Anderson, MD, discusses the recent ODAC decisions for ide-cel and cilta-cel, highlighting clinical trial data supporting the indications.
Camidge and Su Compare Lung Cancer Treatment Strategies in China and the United States
Drs Camidge and Su discuss the aspects of medicine that strengthened Dr Su’s interest in oncology and the details of delivering lung cancer care in…
Next-Generation ColoAlert Screening Test Shows High Sensitivity, Specificity for CRC and Adenoma Detection
Topline findings with the next-generation ColoAlert® test demonstrated 92% sensitivity and 90% specificity rates for colorectal cancer detection.